Investigating DPP4 as a therapeutic target in epithelial ovarian cancer

Ovarian cancer is a lethal disease that urgently requires new therapies. This thesis provides new insight into the role of a protein called DPP4 in ovarian cancer. The studies in this thesis show that DPP4 has potential as a marker for ovarian cancer progression or response to therapy. Targeting DPP4 using a drug called sitagliptin could improve the immune response in patients with late-stage ovarian cancer and shows promise when combined with other therapies. This research shows that using sitagliptin to target DPP4 in ovarian cancer should be considered in clinical trials to improve outcomes for women with this disease.